Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PODD Stock Forecast 2026-2027
$287.70
Current Price
$20.25B
Market Cap
Buy 24
Hold 1
Sell 1
Wall St Analyst Ratings
Distance to PODD Price Targets
+56.4%
To High Target of $450.00
+31.7%
To Median Target of $379.00
-4.8%
To Low Target of $274.00
PODD Price Momentum
+3.3%
1 Week Change
-0.7%
1 Month Change
+4.3%
1 Year Change
+1.2%
Year-to-Date Change
-18.9%
From 52W High of $354.88
+25.1%
From 52W Low of $230.05
📊 TOP ANALYST CALLS
Did PODD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Insulet is one of their latest high-conviction picks.
Latest PODD Stock Price Targets & Analyst Predictions
Based on our analysis of 36 Wall Street analysts, PODD has a bullish consensus with a median price target of $379.00 (ranging from $274.00 to $450.00). The overall analyst rating is Strong Buy (9.2/10). Currently trading at $287.70, the median forecast implies a 31.7% upside. This outlook is supported by 24 Buy, 1 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Kyle Rose at Canaccord Genuity, projecting a 56.4% upside. Conversely, the most conservative target is provided by Matt Miksic at Barclays, suggesting a 4.8% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PODD Analyst Ratings
24
Buy
1
Hold
1
Sell
PODD Price Target Range
Low
$274.00
Average
$379.00
High
$450.00
Current: $287.70
Latest PODD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PODD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 12, 2026 | Barclays | Matt Miksic | Underweight | Downgrade | $274.00 |
| Jan 9, 2026 | Bernstein | Lee Hambright | Outperform | Maintains | $380.00 |
| Dec 18, 2025 | Truist Securities | Richard Newitter | Buy | Maintains | $390.00 |
| Dec 17, 2025 | Canaccord Genuity | Kyle Rose | Buy | Maintains | $450.00 |
| Dec 16, 2025 | Evercore ISI Group | Daniel Markowitz | Outperform | Initiates | $370.00 |
| Nov 24, 2025 | Canaccord Genuity | William Plovanic | Buy | Maintains | $432.00 |
| Nov 21, 2025 | Truist Securities | Richard Newitter | Buy | Maintains | $412.00 |
| Nov 21, 2025 | RBC Capital | Shagun Singh | Outperform | Maintains | $380.00 |
| Nov 21, 2025 | BTIG | Marie Thibault | Buy | Maintains | $380.00 |
| Nov 19, 2025 | UBS | Danielle Antalffy | Buy | Upgrade | $400.00 |
| Nov 13, 2025 | BTIG | Marie Thibault | Buy | Reiterates | $370.00 |
| Nov 7, 2025 | Barclays | Matt Miksic | Equal-Weight | Maintains | $316.00 |
| Nov 7, 2025 | Truist Securities | Richard Newitter | Buy | Reiterates | $390.00 |
| Nov 7, 2025 | Wells Fargo | Lawrence Biegelsen | Overweight | Maintains | $360.00 |
| Nov 7, 2025 | RBC Capital | Shagun Singh | Outperform | Maintains | $370.00 |
| Nov 7, 2025 | UBS | Matthew Taylor | Neutral | Maintains | $355.00 |
| Nov 7, 2025 | Canaccord Genuity | William Plovanic | Buy | Maintains | $428.00 |
| Nov 6, 2025 | Jefferies | Matthew Taylor | Buy | Maintains | $400.00 |
| Nov 5, 2025 | Barclays | Matt Miksic | Equal-Weight | Maintains | $301.00 |
| Oct 21, 2025 | Stifel | Jonathan Block | Buy | Reinstates | $370.00 |
Insulet Corporation (PODD) Competitors
The following stocks are similar to Insulet based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Insulet Corporation (PODD) Financial Data
Insulet Corporation has a market capitalization of $20.25B with a P/E ratio of 84.1x. The company generates $2.52B in trailing twelve-month revenue with a 9.8% profit margin.
Revenue growth is +29.9% quarter-over-quarter, while maintaining an operating margin of +16.7% and return on equity of +19.7%.
Valuation Metrics
Market Cap
$20.25B
Enterprise Value
$20.56B
P/E Ratio
84.1x
PEG Ratio
7.2x
Price/Sales
8.0x
Growth & Margins
Revenue Growth (YoY)
+29.9%
Gross Margin
+72.2%
Operating Margin
+16.7%
Net Margin
+9.8%
EPS Growth
+13.0%
Financial Health
Cash/Price Ratio
+3.7%
Current Ratio
2.9x
Debt/Equity
77.7x
ROE
+19.7%
ROA
+8.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Insulet Corporation (PODD) Business Model
About Insulet Corporation
What They Do
Develops innovative insulin management systems.
Business Model
Insulet Corporation generates revenue primarily through the sale of its Omnipod insulin management systems, including the tubeless wearable insulin pump. The company's business model focuses on providing continuous insulin delivery solutions that enhance the quality of life for diabetes patients, allowing for more freedom and convenience compared to traditional injection methods.
Additional Information
Founded in 2000 and headquartered in Acton, Massachusetts, Insulet has established a strong presence in the international market, with products available in 25 countries and a customer base exceeding 500,000. The company emphasizes research and development to innovate and expand its offerings, while also prioritizing sustainability and social responsibility within the healthcare sector.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
3,900
CEO
Ms. Ashley A. McEvoy
Country
United States
IPO Year
2007
Website
www.insulet.comInsulet Corporation (PODD) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Here's Why Insulet (PODD) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Jan 09, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Insulet Corporation (PODD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
5 days ago
Quick Summary
Insulet Corporation (PODD) presented at the 44th Annual J.P. Morgan Healthcare Conference, highlighting key developments and insights relevant to investors.
Why It Matters
Insulet Corporation's presentation at a major healthcare conference can signal strategic insights, potential growth opportunities, and investor interest, impacting stock performance and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Insulet to Announce Fourth Quarter and Full Year 2025 Financial Results on February 18, 2026
9 days ago
Quick Summary
Insulet Corporation (NASDAQ: PODD) will report its Q4 and full year 2025 financial results on February 18, 2026, before market open, followed by a conference call at 8:00 a.m. ET.
Why It Matters
Insulet's upcoming financial results announcement could indicate its performance trends and growth potential, influencing investor sentiment and stock prices in the diabetes care market.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Zacks Style Scores can help investors identify strong, market-beating stocks for their portfolios.
Why It Matters
The Zacks Style Scores can help identify high-potential stocks, guiding investors towards selections that may outperform the market.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Insulet Corporation (NASDAQ: PODD) will debut at CES 2026, showcasing its vision for liveable technology in connected health through an immersive booth and expert sessions.
Why It Matters
Insulet's presence at CES 2026 highlights its innovation in connected health, potentially attracting investor interest in growth and market leadership in diabetes management technologies.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
PODD is experiencing increased momentum with rising adoption of Omnipod 5, improving margins, and higher earnings estimates, despite facing macroeconomic and concentration risks.
Why It Matters
PODD's accelerating Omnipod 5 adoption and rising margins signal strong demand and profitability, potentially boosting stock performance amid existing risks.
Source: Zacks Investment Research
Market Sentiment:
Positive
Best Growth Stocks to Buy for December 31st
18 days ago
Quick Summary
GLDD, CIEN, and PODD have been rated as Zacks Rank #1 (Strong Buy) growth stocks as of December 31, 2025.
Why It Matters
GLDD, CIEN, and PODD's inclusion in the Zacks Rank #1 list indicates strong growth potential, suggesting these stocks may outperform the market and attract investor interest.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About PODD Stock
What is Insulet Corporation's (PODD) stock forecast for 2026?
Based on our analysis of 36 Wall Street analysts, Insulet Corporation (PODD) has a median price target of $379.00. The highest price target is $450.00 and the lowest is $274.00.
Is PODD stock a good investment in 2026?
According to current analyst ratings, PODD has 24 Buy ratings, 1 Hold ratings, and 1 Sell ratings. The stock is currently trading at $287.70. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PODD stock?
Wall Street analysts predict PODD stock could reach $379.00 in the next 12 months. This represents a 31.7% increase from the current price of $287.70. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Insulet Corporation's business model?
Insulet Corporation generates revenue primarily through the sale of its Omnipod insulin management systems, including the tubeless wearable insulin pump. The company's business model focuses on providing continuous insulin delivery solutions that enhance the quality of life for diabetes patients, allowing for more freedom and convenience compared to traditional injection methods.
What is the highest forecasted price for PODD Insulet Corporation?
The highest price target for PODD is $450.00 from Kyle Rose at Canaccord Genuity, which represents a 56.4% increase from the current price of $287.70.
What is the lowest forecasted price for PODD Insulet Corporation?
The lowest price target for PODD is $274.00 from Matt Miksic at Barclays, which represents a -4.8% decrease from the current price of $287.70.
What is the overall PODD consensus from analysts for Insulet Corporation?
The overall analyst consensus for PODD is bullish. Out of 36 Wall Street analysts, 24 rate it as Buy, 1 as Hold, and 1 as Sell, with a median price target of $379.00.
How accurate are PODD stock price projections?
Stock price projections, including those for Insulet Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 19, 2026 12:49 AM UTC